Clinical trial approval / initiation

Explore the landscape of Clinical trial approval / initiation in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Clinical trial approval / initiation to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio
CompanyDeals

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio

Shionogi & Co., Ltd. (TYO: 4507) announced a definitive agreement to acquire IntraBio, a biopharmaceutical company focused on developing and commercializing therapies for neurodegenerative diseases, for an upfront cash consideration…

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Suzhou Ribo Life Science Receives EU Approval for Phase II Trial of RBD5044
Company

Suzhou Ribo Life Science Receives EU Approval for Phase II Trial of RBD5044

Jiangsu Hengrui Receives NMPA Approval for SHR-2173 Clinical Trial in ITP
CompanyDrug

Jiangsu Hengrui Receives NMPA Approval for SHR-2173 Clinical Trial in ITP

Sino Biopharmaceutical's TQB3002 Receives FDA Clearance for Phase I Study
CompanyDrug

Sino Biopharmaceutical’s TQB3002 Receives FDA Clearance for Phase I Study

Mabwell Bioscience Receives NMPA Approval for 9MW2821 Clinical Trials
CompanyDrug

Mabwell Bioscience Receives NMPA Approval for 9MW2821 Clinical Trials

Jiangxi Jemincare's JMX-2002 Liposome Injection Gets NMPA Clinical Clearance
CompanyDrug

Jiangxi Jemincare’s JMX-2002 Liposome Injection Gets NMPA Clinical Clearance

Lion TCR Gains NMPA Approval for mRNA TCR-T Therapy GZL-016 in HCC
CompanyDrug

Lion TCR Gains NMPA Approval for mRNA TCR-T Therapy GZL-016 in HCC

ImmuneOnco Initiates Phase II Study for IMM27M in ER+ Advanced Breast Cancer
CompanyDrug

ImmuneOnco Initiates Phase II Study for IMM27M in ER+ Advanced Breast Cancer

J&J MedTech Receives FDA IDE for OTTAVA Robotic Surgical System Trials
CompanyMedical Device

J&J MedTech Receives FDA IDE for OTTAVA Robotic Surgical System Trials

Show More